STAT Plus: Telehealth is a ‘silver lining’ of the pandemic, but implementing it permanently won’t be easy
The coronavirus pandemic has stretched hospital resources beyond their capacity, disrupted the delivery of care,…
Category: policy
In unusual revolt, scientists funded by Mark Zuckerberg criticize Facebook’s inaction on President Trump’s posts
Dozens of scientists who have received research funding from Mark Zuckerberg’s philanthropic vehicle have signed…
Trump tries to convince voters he’s lowered drug prices, based only on a modest tweak to Medicare
WASHINGTON — President Trump used a glitzy Rose Garden address, flanked by pharmaceutical company CEOs…
STAT Plus: Pharma panics as Washington pushes to bring drug manufacturing back to the U.S.
WASHINGTON — As the coronavirus pandemic disrupts global supply chains, lawmakers are increasingly calling on…
Opinion: We need a national holiday to honor health policy
Let’s create a holiday for health policy. Not now. But eventually. A holiday that celebrates…
Opinion: We need one response — not 50 — to fight Covid-19
In ordinary times, states handle the public health crises that affect their residents. That usually…
9 ways Covid-19 may forever upend the U.S. health care industry
WASHINGTON — In the U.S. alone, Covid-19 has claimed nearly 100,000 lives and 30 million…
Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?
WASHINGTON — Michelle McMurry-Heath doesn’t talk about biotech the way her peers do. Where other…
A bipartisan group of former health officials seeks to sell a $46.5 billion coronavirus plan to the White House
WASHINGTON — In the past month, President Trump’s senior adviser and son-in-law Jared Kushner has…
Trump announces a formal freeze on WHO funding, pending an investigation
WASHINGTON — President Donald Trump formally announced Tuesday that the United States will freeze funding…
.jpg)
STAT Plus: State legislatures are lapping the federal government on drug pricing — even amid the coronavirus
A version of this article first ran in D.C. Diagnosis, STAT’s weekly newsletter about the…
STAT Plus: Insurers, drug makers, and patient advocates blast two Trump proposals to drive down drug prices
WASHINGTON — The Trump administration has proposed modest steps this year to promote biosimilar and…
The U.S. gets a D- in the coronavirus fight. That stands for ‘disorganization,’ and it’s fixable
NEW YORK — Leora Horwitz has seen other disasters. Now the director of the Center…
STAT Plus: Lawmakers’ coronavirus response means delays for drug pricing legislation
WASHINGTON — Before the coronavirus pandemic became Congress’ sole focus, late May was widely viewed…
STAT Plus: Despite investments and advocacy, pharma’s still making its drugs in batches that can take months — rather than continuously. Why?
WASHINGTON — Former FDA Commissioner Scott Gottlieb said so-called continuous manufacturing would prevent drug shortages,…
‘A number of new stars’: The definitive guide to the Trump administration’s coronavirus response team
WASHINGTON — Vice President Mike Pence is in charge of the Trump administration’s response to…
STAT Plus: Drug companies, Canadians, pharmacists and more blast Trump’s drug importation plan
WASHINGTON — The Trump administration is being flooded with opposition to its plan for allowing…
The coronavirus outbreak has left medical supplies in short supply. Is the nation’s emergency stockpile ready to help?
WASHINGTON — The U.S. government has a secretive, $7 billion stash of emergency medical equipment…
STAT Plus: Private equity firms are increasingly buying up doctors’ offices. What does that mean for doctors — or for patients?
WASHINGTON — Can private equity firms provide quality health care? It’s the question that patients,…
The coronavirus could help pharma reset its reputation in Washington
WASHINGTON — The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation…
Partisan bickering delayed Zika funding for months. With coronavirus, experts worry history will repeat itself
WASHINGTON — Public health experts have a warning for Congress: don’t treat emergency coronavirus aid…
STAT Plus: Trump’s Medicaid changes offers states new powers to lower drug costs — with a catch
WASHINGTON — The Trump administration on Thursday unveiled a powerful new tool for states to…
STAT Plus: With new rules, FDA aims to spark competition, lower prices for expensive gene therapies
WASHINGTON — The Food and Drug Administration released a slew of gene therapy policies Tuesday…
STAT Plus: Prosecutors identified ‘Pharma Co. X’ as central to alleged opioid kickback scheme. Was it Purdue?
Federal prosecutors this week announced a $145 million settlement with an electronic health records company…
It’s the insulin, stupid: How drug pricing’s simplest case study became a top issue for 2020 Democrats
WATERLOO, Iowa — Presidential candidates can’t stop talking about insulin. At a campaign stop here…
Want to know how contentious drug pricing is in Washington? Check the receipts
WASHINGTON — Pfizer, Johnson & Johnson, Merck and the 31 other major drug makers that…
FDA and NIH let clinical trial sponsors keep results secret, investigation shows
This story was originally published by Science. It is a follow-up to STAT articles in…
Trump touted a new antidepressant as a solution for veterans. Only 15 have been treated
In August, President Trump proudly proclaimed that he had directed the Department of Veterans Affairs…
3 drug pricing policy experiments to watch in 2020
WASHINGTON — Politicians spent the better part of 2019 bickering over the best way to…
3 congressional races to watch in 2020
WASHINGTON — Drug prices are on the ballot once again in 2020. It’s already evident…
2019 was supposed to be the year Washington lowered drug prices. What happened?
WASHINGTON — Lawmakers of all stripes made an agreement the day following the midterm elections…
STAT Plus: One drug maker has a lot more to lose than others, under early drafts of drug importation plans
WASHINGTON — President Trump’s plan to let states and drug wholesalers import medicines from Canada…
Top Republican blasts McConnell for derailing bipartisan drug pricing bill
WASHINGTON — Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.), the bipartisan duo behind the…
STAT Plus: Lawmakers slip a win for pharma into federal spending package
WASHINGTON — Lawmakers quietly tucked a boost for the pharmaceutical industry in the massive, end-of-year…
It’s a bonanza: With drug pricing bill up for a vote, D.C. news outlets are drowning in advocacy ads
WASHINGTON — Pick up this morning’s print edition of Politico and you’ll be hard-pressed to…
Democrats’ drug pricing bill is a sneak peek at the party’s 2020 campaign message
WASHINGTON — If Democrats are spoiling for a 2020 fight focused on anything besides impeaching…
STAT Plus: With new trade deal, Trump deals a blow to drug makers
WASHINGTON — The Trump administration’s Tuesday agreement on a new trade deal with Canada and…
STAT Plus: House Republicans fuel Capitol Hill chaos with competing drug pricing bill
WASHINGTON — Republicans on Monday are set to accelerate Capitol Hill’s drug pricing chaos with…
Revamped, bipartisan Senate package takes aim at drug prices — and props up other health programs, too
WASHINGTON — Leaders of a key Senate committee unveiled a new version of a sweeping,…
STAT Plus: More than 100 small biotech CEOs sound off against Pelosi’s signature drug pricing bill
WASHINGTON — Nearly 150 CEOs of emerging biotech companies are sending a unified, stark message…
STAT Plus: Congress is hoping for another major medical research bill. But pharma’s not nearly as excited as before
WASHINGTON — The bipartisan duo behind a 2016 law that poured billions into medical research…
How a billionaire couple greased the skids for Nancy Pelosi’s drug pricing bill
WASHINGTON — When House Democrats pass legislation next month that would slash prescription drug spending…
STAT Plus: ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
CAMBRIDGE, Mass. — Biopharma’s reputation is, objectively speaking, the worst. And on Thursday, several biotech…
STAT Plus: Biotech venture capitalists form a lobbying coalition to join the drug pricing debate
A shorter version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about…